Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 65

Using Tenofovir Disoproxil Fumarate to treat Parkinson's Disease

Official title: Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

Run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · NCT06356662 · Data updated 2026-11-12

This study tests if a medication called tenofovir disoproxil fumarate can help improve movement symptoms in people with early-stage Parkinson's disease.

More Parkinson Disease trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedJanuary 23, 2024
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedFebruary 17, 2025
Trial IDNCT06356662 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals diagnosed with early-stage Parkinson's disease, specifically those with a Hoehn Yahr stage of 1 to 2.5 and a Mini-Mental State Examination (MMSE) score of 24 or higher.

Probably not a fit

Patients with other neurological disorders, severe psychiatric conditions, or significant comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of tenofovir disoproxil fumarate in patients with early-stage Parkinson's disease. It compares changes in motor symptoms and the occurrence of adverse reactions between patients taking the drug and those not taking it at various time points. The study aims to determine whether this medication can improve symptoms associated with Parkinson's disease.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for managing Parkinson's disease symptoms.

How similar studies have gone: While the use of tenofovir disoproxil fumarate in Parkinson's disease is a novel approach, similar studies targeting neurodegenerative conditions have shown promise in the past.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24

Exclusion Criteria:

* 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders

  2: Or have received deep brain stimulation and other brain surgery

  3: Abnormal liver and kidney function

  4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)

  5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence

  6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor

  7: Pregnant or lactating women and seniors over 65 years of age

  8: Allergy or other contraindications to the investigational drug

Where it's running

  • Guohua Zhao
    Hangzhou, Zhejiang, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.